Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit

Core Insights - Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for neurologic diseases [2] - The company is developing three key assets: AJ201 for spinal and bulbar muscular atrophy, BAER-101 for CNS diseases, and IV tramadol for acute postoperative pain management [2] - The CEO, Dr. Alexandra MacLean, will participate in a fireside chat at Maxim Group's 2024 Healthcare Virtual Summit on October 15, 2024 [1] Company Overview - Avenue Therapeutics is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. [2] - The company is publicly traded on Nasdaq under the ticker ATXI [2] - Avenue Therapeutics is focused on innovative treatments for neurologic conditions, indicating a strategic emphasis on niche therapeutic areas [2]